These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19710077)

  • 21. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD; Cho HY; Lee YB
    Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
    Acosta EP; Kendall MA; Gerber JG; Alston-Smith B; Koletar SL; Zolopa AR; Agarwala S; Child M; Bertz R; Hosey L; Haas DW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3104-10. PubMed ID: 17576825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond Single Nucleotide Polymorphisms:
    Brazeau DA; Attwood K; Meaney CJ; Wilding GE; Consiglio JD; Chang SS; Gundroo A; Venuto RC; Cooper L; Tornatore KM
    Front Genet; 2020; 11():889. PubMed ID: 32849848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of
    Singkham N; Avihingsanon A; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Burger DM; Emery S; Punyawudho B
    Pharmacogenomics; 2019 May; 20(7):517-527. PubMed ID: 31124411
    [No Abstract]   [Full Text] [Related]  

  • 31. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
    HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
    Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
    J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
    Belkhir L; Elens L; Zech F; Panin N; Vincent A; Yombi JC; Vandercam B; Haufroid V
    PLoS One; 2016; 11(10):e0165631. PubMed ID: 27788239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A maintenance dose of atazanavir/ritonavir 200/100 mg once daily is effective in virologically suppressed HIV-1-infected patients.
    Lanzafame M; Lattuada E; Rigo F; Vento S
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):e81-2. PubMed ID: 23666142
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
    DiCenzo R; Peterson DR; Cruttenden K; Mariuz P; Rezk NL; Hochreiter J; Gelbard H; Schifitto G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3035-9. PubMed ID: 18573930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.